Search research articles
Contact Us
Filters
Showing results (151-160 of 163) with videos related to
Page
of 17
Sort By:
Cancer Immunology Research
|
July 12, 2018
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
Fernando C Santini, Hira Rizvi, Andrew J Plodkowski, et al.
FEBS Letters
|
May 20, 2000
Activation of PPARdelta alters lipid metabolism in db/db mice
M D Leibowitz, C Fiévet, N Hennuyer, et al.
JTO Clinical and Research Reports
|
July 21, 2025
A Phase II Study of Cabozantinib in Patients With <i>MET</i>-Altered Lung Cancers
Guilherme Harada, Fernando C Santini, Clare J Wilhelm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 28, 2024
A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
Noura J Choudhury, W Victoria Lai, Alex Makhnin, et al.
Future Oncology (London, England)
|
November 5, 2020
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated <i>RET</i> positive non-small-cell lung cancer
Benjamin J Solomon, Cai Cun Zhou, Alexander Drilon, et al.
Acta Diabetologica
|
January 30, 2008
Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: an Italian experience
Annunziata Lapolla, M G Dalfrà, R Spezia, et al.
Frontiers in Bioscience (Landmark Edition)
|
January 2, 2013
Biomarker discovery by plasma proteomics in familial Brugada Syndrome
M Di Domenico, D Scumaci, S Grasso, et al.
The Journal of Biological Chemistry
|
February 26, 1999
Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects
J Berger, M D Leibowitz, T W Doebber, et al.
The New England Journal of Medicine
|
October 23, 2023
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion-Positive NSCLC
Caicun Zhou, Benjamin Solomon, Herbert H Loong, et al.
European Journal of Nutrition
|
December 23, 2016
Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The TOSCA.IT Study
M Vitale, M Masulli, A A Rivellese, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 163) with videos related to
Sort By:
Page
of 17
Cancer Immunology Research
|
July 12, 2018
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
Fernando C Santini, Hira Rizvi, Andrew J Plodkowski, et al.
FEBS Letters
|
May 20, 2000
Activation of PPARdelta alters lipid metabolism in db/db mice
M D Leibowitz, C Fiévet, N Hennuyer, et al.
JTO Clinical and Research Reports
|
July 21, 2025
A Phase II Study of Cabozantinib in Patients With <i>MET</i>-Altered Lung Cancers
Guilherme Harada, Fernando C Santini, Clare J Wilhelm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 28, 2024
A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
Noura J Choudhury, W Victoria Lai, Alex Makhnin, et al.
Future Oncology (London, England)
|
November 5, 2020
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated <i>RET</i> positive non-small-cell lung cancer
Benjamin J Solomon, Cai Cun Zhou, Alexander Drilon, et al.
Acta Diabetologica
|
January 30, 2008
Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: an Italian experience
Annunziata Lapolla, M G Dalfrà, R Spezia, et al.
Frontiers in Bioscience (Landmark Edition)
|
January 2, 2013
Biomarker discovery by plasma proteomics in familial Brugada Syndrome
M Di Domenico, D Scumaci, S Grasso, et al.
The Journal of Biological Chemistry
|
February 26, 1999
Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects
J Berger, M D Leibowitz, T W Doebber, et al.
The New England Journal of Medicine
|
October 23, 2023
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion-Positive NSCLC
Caicun Zhou, Benjamin Solomon, Herbert H Loong, et al.
European Journal of Nutrition
|
December 23, 2016
Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The TOSCA.IT Study
M Vitale, M Masulli, A A Rivellese, et al.
Page
of 17